MedTrace Logo

Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors

NCT04875871 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-05-11

No results posted yet for this study

Summary

This study uses a novel, recently developed unconventional radiotherapy technique which consists of three high-dose fractions directed to special segments of unresectable bulky tumors.

Conditions

Interventions

RADIATION

Particle radiotherapy

Partial radiotherapy targeting the hypoxic tumor segment

DIAGNOSTIC_TEST

Magnetic resonance imaging

For treatment planning as well as for follow-up radiological tumor assessment.

DIAGNOSTIC_TEST

Computertomography

For treatment planning as well as for follow-up radiological tumor assessment.

DIAGNOSTIC_TEST

Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)

For the definition of the hypoxic tumor segment in treatment planning.

DIAGNOSTIC_TEST

18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)

For follow-up radiological tumor assessment.

DIAGNOSTIC_TEST

Blood sampling

Evaluation before treatment-start, during treatment and follow-up period.

Sponsors & Collaborators

  • Medical University of Vienna

    collaborator OTHER

  • Landesklinkum Wiener Neustadt

    collaborator OTHER

  • Klinik Ottakring

    collaborator UNKNOWN

  • EBG MedAustron GmbH

    lead INDUSTRY

Principal Investigators

  • Slavisa Tubin, M.D. · EBG MedAustron

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2025-03-14
Completion
2025-03-14

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04875871 on ClinicalTrials.gov